Marathon Pharma sells non-strategic products to Valeant

24 February 2015

Marathon Pharmaceuticals, a privately held US biopharmaceuticals company focused on drugs for people with rare diseases, says it has made significant progress with its rare disease pipeline and expects several approvals and product launches beginning in 2016.

In preparation for rolling out its new rare disease treatments, Marathon sold its portfolio of non-strategic products to a unit of Canada-based Valeant Pharmaceutical International (TSX: VRX).

Financial terms of the accord were not disclosed, but the cost will be small-fry compared with Valeant’s recent decision to acquire Salix Pharmaceuticals (Nasdaq: SLXP) for around $10 billion (The Pharma Letter February 23).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK